Biogen's $5.6B Apellis Acquisition: Key Biotech Deals Including Telix's $600M Raise and Obsidian's IPO Plans

on

Biogen agreed to acquire Apellis Pharmaceuticals for at least $5.6 billion, paying $41 per share in cash (140% premium to recent closing price) plus potential $4 per share CVRs tied to Syfovre sales milestones.123

The deal adds Apellis' approved products Syfovre (for geographic atrophy) and Empaveli (for rare blood/kidney disorders), which generated $689 million in 2025 revenue, expected to grow at mid-to-high teens through 2028.34

Acquisition supports Biogen's felzartamab launch in kidney diseases and diversifies into immunology/rare diseases; expected to close Q2 2026.345

Note:
Search results detail Biogen-Apellis deal extensively; no specific details found on Telix's $600M raise or Obsidian's public listing in provided sources.

Sources:

1. https://www.biopharmadive.com/news/biogen-apellis-acquisition-deal-immune-syfovre-empaveli/816233/

2. https://www.pharmaceutical-technology.com/news/biogen-acquires-apellis-pharmaceuticals-5-6bn/

3. https://www.retinalphysician.com/news/2026/biogen-announces-56-billion-apellis-deal/

4. https://globalgenes.org/raredaily/biogen-to-acquire-apellis-is-5-6-billion-deal/

5. https://www.biospace.com/business/biogen-secures-running-start-in-kidney-disease-with-5-6b-apellis-buy